Respiratory Disease Testing Market Expected to Reach USD 3.1 Billion Globally in 2022 -Transparency Market Research

Based on type of test, the respiratory disease testing market has been segmented into imaging, spirometry, peak flow, blood gas, lung volume, and other tests. Imaging tests accounted for the largest share of the global respiratory disease testing market in 2013. The segment dominated the market primarily due to widespread adoption of imaging measures, especially X-ray. In addition, these tests are considered first-line of diagnostic tests for respiratory diseases. However, the spirometry test segment is projected to expand at the highest CAGR during the forecast period due to accurate and effective diagnostic result in a short timespan and preference by physicians in lung function testing for their patients. In addition, introduction of new and advanced, but cost-efficient devices would propel the growth of the segment. Other factors that would increase global demand for respiratory disease testing equipment include rising prevalence of respiratory diseases and technological advancements in the respiratory disease equipment. On the other hand, low adoption rate of advanced equipment due to high cost and limited application areas are factors that could restrict demand for respiratory disease testing equipment.

 

Hospitals accounted for the largest share of the global respiratory disease testing market in 2013. The segment dominated the market as most of the respiratory diagnostic instruments, especially X-ray machines and spirometers are predominantly installed and used in hospital settings. Moreover, these devices are expensive and small clinics and laboratories cannot afford them for diagnostic purposes. Furthermore, physicians prefer in-house alternatives to imaging tests for patients rather than referring them to outside laboratories. Hence, hospitals are likely to continue to act as viable alternatives, and would capture market shares of the clinical laboratories and physician offices segments during the study period. Therefore, the hospitals segment of the respiratory disease testing market is expected to grow at the highest CAGR between 2014 and 2022. 

 

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1288

 

The global respiratory disease testing market is highly fragmented, with the presence of a large number of small and multinational players. CareFusion Corporation (Complete PFT), Carestream Health, Inc. (CARESTREAM DRX-1 System), Cosmed (Quark SPIRO), GE Healthcare (Discovery XR656 Plus), and Perkin Elmer, Inc. (Flat panel X-ray detectors) are the key players operating in the global respiratory disease testing market. 

 

Browse the full Respiratory disease Testing Market (By Tests - Imaging, Spirometry, Peak Flow, Blood Gas, Lung Volume, and Other Tests); (By End-User - Hospitals, Physician Offices and Clinical Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at http://www.transparencymarketresearch.com/ respiratory-disease-testing.html

 

The global respiratory disease testing market is segmented as follows: